Levocarnitine Aspire Pharma

Levocarnitine, the active ingredient in Levocarnitine Aspire Pharma, is an L‑carnitine presented as an oral formulation for oral use. It is indicated for the treatment of primary or secondary carnitine deficiency and to support fatty‑acid metabolism in individuals requiring nutritional supplementation.

GNH USA supplies Levocarnitine Aspire Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality assurance, regulatory compliance, and reliable logistics for global distribution through its extensive network of certified partners.

Levocarnitine is used to address disorders of carnitine metabolism and related energy‑deficiency conditions.

- Carnitine deficiency: restores intracellular carnitine levels to improve fatty‑acid oxidation. - Primary metabolic disorders: supports energy production in inherited fatty‑acid oxidation defects. - Post‑transplant care: helps maintain metabolic balance in patients receiving organ transplants. - Renal dialysis patients: compensates for carnitine loss during dialysis to aid muscle function. - Athletic performance support: may assist in reducing fatigue during prolonged exercise in individuals with low carnitine.

Levocarnitine is generally well tolerated, but some users may experience adverse reactions.

Common Side Effects: - Nausea: mild stomach upset reported in some patients. - Diarrhea: loose stools occurring after oral intake. - Headache: transient mild headache. - Metallic taste: temporary taste alteration in the mouth.

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, itching, or swelling indicating an allergic response. - Muscle weakness: rare occurrence of unexplained muscle fatigue. - Seizures: extremely rare neurological events reported in isolated cases.

When considering levocarnitine, certain precautions should be observed to ensure safe use.

- Assess renal function: dosage may need adjustment in patients with severe kidney impairment. - Monitor cardiac status: patients with heart disease should be evaluated for metabolic response. - Review concomitant medications: consider potential interactions with antiepileptic drugs. - Pregnancy and lactation: use only if clearly needed, as safety data are limited. - Pediatric use: dosage for children should be determined by a qualified healthcare professional. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Levocarnitine may interact with certain medicines, affecting its absorption or metabolic effects.

Major Interactions (Avoid): - Valproic acid: may reduce levocarnitine effectiveness and increase risk of deficiency. - Certain antibiotics (e.g., cefoperazone): can interfere with carnitine metabolism.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenobarbital): may increase carnitine clearance. - Dialysis fluids: high‑flux dialysis can remove levocarnitine, requiring supplemental dosing. - Thyroid hormones: may alter carnitine requirements, necessitating monitoring.